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ABSTRACT
Posttranslational histone modifications associated
with actively expressed genes are generally
believed to be introduced primarily by histone-
modifying enzymes that are recruited by transcrip-
tion factors or their associated co-activators. We
have performed a comprehensive spatial and tem-
poral analyses of the histone modifications that are
deposited upon activation of the MHC class II gene
HLA-DRA by the co-activator CIITA. We find that
transcription-associated histone modifications are
introduced during two sequential phases. The first
phase precedes transcription initiation and is char-
acterized exclusively by a rapid increase in histone
H4 acetylation over a large upstream domain. All
other modifications examined, including the acet-
ylation and methylation of several residues in
histone H3, are restricted to short regions situated
at or within the 50 end of the gene and are
established during a second phase that is concom-
itant with ongoing transcription. This second phase
is completely abrogated when elongation by RNA
polymerase II is blocked. These results provide
strong evidence that transcription elongation can
play a decisive role in the deposition of histone
modification patterns associated with inducible
gene activation.
INTRODUCTION
The basic building block of eukaryotic chromatin is the
nucleosome, which consists of 147 bp of DNA wrapped
around an octamer of the four core histone proteins H3,
H4, H2A and H2B. The packaging of DNA into
nucleosomes creates a restrictive environment that reduces
the accessibility of DNA to factors that mediate
chromatin-templated processes such as transcription.
Dynamic structural rearrangements that render the
chromatin permissive for transcription are therefore
intimately associated with the regulation of gene expres-
sion. These structural rearrangements are believed to be
facilitated by various posttranslational modiﬁcations of
nucleosomal histones that aﬀect chromatin structure
either directly or by creating docking sites for the
recruitment of eﬀector proteins [for recent reviews see
(1–3)].
Among the most well-documented modiﬁcations asso-
ciated with actively transcribed genes are the acetylation
of various lysine residues in the N-terminal tails of H3 and
H4 (H3Ac and H4Ac) (1), the di- and tri-methylation of
lysine 4 in the N-terminal tail of H3 (H3K4Me2 and
H3K4Me3) (2) and the methylation of arginine 17 in the
N-terminal tail of H3 (H3R17Me2) (3). More recently, it
has been shown that the methylation of lysine 9 in the
N-terminal tail of H3 (H3K9Me3)—a modiﬁcation that
was until then thought to be a hallmark of silent
heterochromatin (2)—is actually also found within the
50 ends of several actively transcribed mammalian
genes (4). It is now well established from studies in
multiple model systems and species that there is a tight
correlation between the presence of these histone mod-
iﬁcations and active gene expression (1–3). A widespread
view is that histone-modifying activities are recruited by
transcription factors and/or associated co-activators,
and that they impact primarily on assembly of the
general transcription machinery and transcription initia-
tion (1–3,5). However, there is also growing evidence
suggesting that factors associated with elongating RNA
polymerase can play a key role in establishing histone
modiﬁcations associated with actively expressed genes
(2,6–11).
A full understanding of the mechanisms that mediate
the deposition and functional consequences of speciﬁc
histone modiﬁcation patterns requires the analysis and
integration of at least three related parameters: where in
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the gene the various diﬀerent histone modiﬁcations are
made, in what temporal order they are introduced and
what steps in the transcription process they are implicated
in (12–16). Yet in the majority of higher eukaryotic
systems these three parameters have not been integrated
into a single comprehensive and dynamic description of
the spatial distribution and temporal order of chromatin
modiﬁcation events that occur during the activation of
transcription. We have performed such an analysis in one
of the most well-deﬁned human model systems, the
activation of major histocompatibility complex class II
(MHC-II) genes (17–19).
Two modes of MHC-II expression, constitutive and
inducible, are recognized (17–19). Constitutive expression
is restricted mainly to specialized cells of the immune
system (thymic epithelial cells, dendritic cells, macro-
phages and B cells). Most other cell types do not express
MHC-II genes unless they are exposed to interferon-g
(IFN-g). The molecular machinery that regulates MHC-II
expression has been exceptionally well deﬁned thanks to
the elucidation of the genetic defects that are responsible
for the Bare Lymphocyte Syndrome, a rare hereditary
immunodeﬁciency disease resulting from mutations in
genes encoding transcription factors that are essential for
MHC-II expression (17,20–24). One of these factors, the
class II transactivator (CIITA) (20), is a transcriptional
co-activator that is exquisitely speciﬁc for the activation of
MHC-II genes (Figure 1A). CIITA serves as the master
regulator of MHC-II genes and is expressed in a cell-type-
speciﬁc and IFN-g-inducible manner that dictates both the
constitutive and inducible patterns of MHC-II expression
(19). It is recruited to the regulatory regions of MHC-II
genes by protein–protein interactions with a multi-protein
‘enhanceosome’ complex that assembles on a character-
istic enhancer known as the MHC-II S-Y module
(Figure 1A) (17,18,25–29). A heterotrimeric DNA-binding
factor called regulatory factor X (RFX) is a central
component of the enhanceosome complex (Figure 1A)
(17,21–24).
The activation of MHC-II genes by CIITA is associated
with an increase in many of the major histone modiﬁca-
tions known to correlate with active transcription,
including H3Ac, H4Ac, H3K4Me2, H3K4Me3 and
H3R17Me2 (26–32). Most studies examining these mod-
iﬁcations have restricted themselves to the promoters of
MHC-II genes (28,30–32), despite the fact that several
reports have shown that they may aﬀect distal regions as
well (26,27,29). Moreover, only limited information is
available on when and in what order these modiﬁcations
are introduced during the activation process (28,29,32).
We have therefore performed a comprehensive analysis of
the spatial distribution, order and timing of the histone
modiﬁcations that are introduced during IFN-g-induced
activation of the prototypical MHC-II gene HLA-DRA.
We demonstrate that there are two spatially and
temporally distinct chromatin-modiﬁcation phases.
The ﬁrst phase precedes the initiation of transcription
and is characterized by a global increase in H4 acetylation
throughout a large upstream domain. All other modiﬁca-
tions are restricted to short regions situated within or near
the 50 end of the gene and are introduced in a second phase
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Figure 1. Precise timing of IFN-g-induced HLA-DRA expression.
(A) Molecular mechanism mediating IFN-g-induced HLA-DRA expres-
sion. IFN-g induces rapid expression of the gene coding for the
transcriptional co-activator CIITA, which activates transcription of the
HLA-DRA gene by associating with an enhanceosome complex that
assembles at its proximal (S-Y) and distal (S0-Y0) regulatory modules.
RFX is a key component of the enhanceosome complex. (B) Cell
surface HLA-DR expression was measured by FACS in Me67.8 cells
stimulated with IFN-g for 0, 24 and 48 h. (C) The accumulation of
CIITA and HLA-DRA mRNAs were quantiﬁed by real-time RT-PCR
in IFN-g-stimulated Me67.8 cells over a 48-h time period. Shading
highlights a 4-h lag period between the induction of CIITA and
HLA-DRA mRNA accumulation. Results are expressed relative to the
values measured after 48 h. The mean and SD are shown for four
experiments. (D) Occupation of the HLA-DRA S-Y and S0-Y0 modules
by CIITA and RFX was measured by quantitative chromatin
immunoprecipitation (ChIP) at the indicated times following stimula-
tion with IFN-g. Shaded bars highlight the occupation that is induced
during the lag period preceding HLA-DRA gene activation. Results are
expressed relative to the plateau values reached after 12 h. The mean
and SD are shown for two experiments.
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that coincides with, and is a consequence of, ongoing
transcription. With the exception of H4Ac, most mod-
iﬁcations observed at the HLA-DRA gene are thus
established by transcription-coupled mechanisms.
MATERIALS AND METHODS
Cells
Me67.8 cells were grown in RPMIþGlutamax medium
(Invitrogen) supplemented with 10% fetal calf serum and
antibiotics, and were induced with 200U/ml of human
IFN-g (Invitrogen) as described (33). Cell surface HLA-
DR expression was analyzed by FACS as described (34).
DRB (Sigma) was added to culture medium at a
concentration of 100 mM.
Chromatin immunoprecipitation (ChIP)
Chromatin preparation and ChIP experiments were
performed as described using antibodies speciﬁc for
RFX, CIITA and modiﬁed histones (26,27,31). Results
for modiﬁed histones were normalized using the TATA-
binding protein (TBP) promoter as internal control and
were compensated for ﬂuctuations in nucleosome density
by performing ChIP experiments in parallel with an
antibody against unmodiﬁed H3. Histone antibodies were
obtained from Abcam, Cambridge, UK (H3, Ab1791;
H4K5Ac, Ab1758; H3K4Me3, Ab8580; H3K4Me2,
Ab7766; H3K9Me3, Ab8898; H3K36me3, Ab9050) or
Upstate, Lake Placid, NY (H4Ac, 06-866; H4K8Ac, 07-
328; H4K12Ac, 07-595; H4K16Ac, 07-329; H3Ac, 06-599;
H3K9Ac, 07-352; H3K14Ac, 07-353; H3K23Ac, 07-355;
H3K27Ac, 07-360; H3R17Me3, 07-214). The RNA Pol II
antibody was from Abcam (Ab817). Results were
generated by real-time PCR using the primers listed in
Supplementary Table 1. PCR was performed using the
iCycler iQ Real-Time PCR Detection System (BioRad)
and a SYBR-Green-based kit for quantitative PCR (iQ
Supermix—BioRad). Ampliﬁcation speciﬁcity was con-
trolled by gel electrophoresis and dissociation curve
analysis. Results were quantiﬁed using a standard curve
generated with serial dilutions of input DNA. PCR
ampliﬁcations were performed in triplicate. Experiments
were repeated between two and ﬁve times with diﬀerent
inductions.
RNA quantification
CIITA and DRA mRNAs were quantiﬁed by real-time
RT-PCR and normalized with respect to TBP mRNA as
described (31,34). Chromatin-bound nascent and inter-
genic transcripts were isolated and quantiﬁed by real-time
RT-PCR as described (26). Primers used for nascent and
intergenic transcripts are listed in Supplementary Table 1.
PCR measurements were made in triplicate. Experiments
were repeated between two and four times with diﬀerent
inductions.
Immunoblotting
Cells were lysed for 1 h on ice in 50mM Tris-HCl, pH 7.4,
150mM NaCl, 10mM EDTA, 1% NP40, 1mM DTT
containing 1 completeTM protease inhibitors (Roche)
and a phosphatase inhibitor cocktail (Sigma). Lysates
were clariﬁed by centrifugation and protein concentra-
tions were determined. Proteins were dissolved in 2
sample buﬀer and equal amounts were fractionated by
SDS-PAGE. Proteins were transferred to Immobilon-P
membranes (Millipore), which were incubated with rabbit
polyclonal CARM1 antibodies (Upstate 07-080, used at
1/1000 dilution), rabbit polyclonal CBP antibodies
(SantaCruz sc-369, used at 1/500 dilution), rabbit poly-
clonal pCAF antibodies (Abcam ab12188, gift from
W. Herr, used at 1/600 dilution), rabbit polyclonal Set1c
antibodies (gift from W. Herr, used at 1/500 dilution),
rabbit polyclonal WDR5 antibodies (gift from W. Herr,
used at 1/500 dilution) and mouse monoclonal
S2-phosphorylated-Pol II antibodies (Covance, MMS-
129R). Detection was performed using peroxidase con-
jugated anti-mouse or anti-rabbit IgG antibodies
(Promega) and chemiluminescence visualization (ECL,
Amersham) according to the manufacturer’s instructions.
Blots were quantiﬁed using Quantity One software.
RESULTS
Precise timing of IFN-g-inducedHLA-DRA gene
transcription
Histone modiﬁcations introduced during IFN-g-induced
activation of the HLA-DRA gene were studied in the
melanoma cell line Me67.8, which was chosen because it
exhibits a robust and reproducible induction of CIITA
and MHC-II expression in response to INF-g (Figure 1A)
(33). Me67.8 cells respond to IFN-g in a synchronized
manner, such that the entire population exhibits a
homogeneous shift over time in the level of cell surface
MHC-II expression (Figure 1B).
Time course experiments were performed to document
the activation of CIITA and HLA-DRA mRNA expres-
sion (Figure 1C), as well as occupation of the HLA-DRA
S-Y modules by CIITA and RFX (Figure 1D). The time
courses obtained for these parameters are highly repro-
ducible from one experiment to another (see error bars in
Figure 1). CIITA mRNA accumulation starts 2 h after
induction, whereas the increase inHLA-DRAmRNA only
becomes evident after 6 h (Figure 1C). During this 4-h lag
period, occupation of the S-Y modules by CIITA and
RFX increases to reach a plateau by 6 h (Figure 1D).
These results deﬁne a precise 4-h time window during
which key events implicated in CIITA-mediated transcrip-
tional initiation of the HLA-DRA gene are most likely to
occur.
Two distinct phases of histone acetylation
We performed chromatin immunoprecipitation (ChIP)
experiments to examine changes in the levels of H3Ac and
H4Ac that are induced over time within a 7-kb domain
that spans 5 kb of the upstream regulatory region and 2 kb
of the 50 end of the HLA-DRA gene. Two spatially and
temporally distinct histone acetylation phases were
evident (Figure 2). During the ﬁrst phase, there was a
strong increase in H4Ac over the entire region examined.
This global increase in H4Ac was ﬁrst evident after 3 h of
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induction and reached nearly maximal levels by 6 h.
During the second phase, there was an increase in H3Ac
that was restricted to a short 1-kb region situated within
the 50 end of the gene. This local increase in H3Ac
occurred mainly between 6 and 12 h after the start of
induction.
To deﬁne the precise lysine (K) residues that are
implicated in the two phases, we performed ChIP
experiments with antibodies directed against speciﬁc
acetylated K residues of histones H4 and H3. During
the ﬁrst phase, H4 was acetylated mainly at K5 and K8
(Figure 3A). No obvious increases in the acetylation of
H4K12 and H4K16 were evident (Figure 3A).
As observed for H4Ac, the increases in H4K5Ac and
H4K8Ac were early events that were essentially complete
by 6 h of induction (Figure 3A) and concerned the entire
7-kb region (Figure 3B). During the second phase, the
strongest increase in acetylation was observed at K9 of H3
(Figure 4A). There was a more modest increase for
acetylation at H3K14, whereas no obvious changes were
evident for acetylation at H3K23 and H3K27 (Figure 4A).
As for H3Ac, the increase in H3K9Ac was a late event
occurring mainly after 6 h of induction (Figure 4A) and
was restricted to the 50 end of the gene (Figure 4B).
The acetylation speciﬁcity that we observed is consistent
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Figure 3. Speciﬁcity of H4 acetylation induced at the HLA-DRA gene.
(A) The levels of acetylation at lysines K5, K8, K12 and K16 of H4
were measured by quantitative ChIP at the HLA-DRA promoter after
induction with IFN-g for the indicated times. Similar results were
obtained at the other positions in the region analyzed in (B) (data not
shown). (B) Acetylation at H4K5 and H4K8 was measured by
quantitative ChIP at the indicated positions in the HLA-DRA gene
after 0 and 12 h of induction. All results are expressed relative to the
value observed at the promoter in non-induced cells. The mean and SD
are shown for two experiments.
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Figure 2. Spatial and temporal patterns of the induction of histone
acetylation at the HLA-DRA gene. (A) The levels of H4 (top, H4Ac)
and H3 (bottom, H3Ac) acetylation were measured by quantitative
ChIP at diﬀerent positions within the HLA-DRA gene in non-induced
cells and cells treated with IFN-g for 12 h. A schematic map of the
HLA-DRA gene is shown below. (B) The levels of H4 (left) and H3
(right) acetylation were measured by quantitative ChIP at the indicated
positions after induction with IFN-g for the indicated times. For H4Ac,
similar time courses were also observed at the other positions examined
in (A) (data not shown). Asterisk denotes not measured in all
experiments. All results are expressed relative to the value observed
at the promoter in non-induced cells. The mean and SD are shown for
four (H4Ac) and ﬁve (H3Ac) experiments.
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with previous reports showing that H4K8 and H3K9 are
among the major residues that are acetylated at the HLA-
DRA promoter in B cells and IFN-g-induced cells (29,30).
To situate the two phases of histone acetylation with
respect to the initiation of transcription, we performed
ChIP experiments to determine the timing of Pol II
recruitment at the HLA-DRA promoter and the appear-
ance of nascent chromatin-bound HLA-DRA transcripts
(Figure 5A). Pol II recruitment coincided with the increase
in H4 acetylation and reached nearly maximal levels by
6 h. In contrast, nascent transcripts appeared mainly after
6 h, in parallel with the increase in H3 acetylation.
The ﬁrst phase of H4 acetylation is thus associated with
Pol II recruitment but precedes the initiation of transcrip-
tion. In contrast, the subsequent H3 acetylation phase
appeared to coincide with active transcription. To conﬁrm
the latter, we performed a ﬁner time course between 6 and
12 h (Figure 5B). The results indicate that the increase in
H3 acetylation and the appearance of nascent transcripts
are simultaneous events.
H4 acetylation is associated with intergenic transcription
Constitutive expression of the HLA-DRA gene in B cells is
associated with intergenic transcription of its upstream
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Figure 5. Temporal relationship between the induction of histone
acetylation, the recruitment of Pol II and the initiation of transcription.
(A) H4 acetylation, H3 acetylation, recruitment of Pol II and the
appearance of nascent chromatin-bound transcripts were quantiﬁed
after the indicated times in IFN-g-induced cells. For H4Ac, the results
represent the mean and SD for measurements made in three to four
experiments at four positions (1.3, 0.1, þ0.3 and þ0.6 kb) in the
HLA-DRA gene. For H3Ac, the results represent the mean and SD for
measurements made in three to ﬁve experiments at three positions
(0.1, þ0.3 and þ0.6 kb) in the HLA-DRA gene. For nascent
transcripts, the results represent the mean and SD for measurements
made in two experiments at three positions (þ0.3, þ0.6 and þ1.7 kb)
within the HLA-DRA gene. For Pol II, results represent the mean and
SD for measurements made at the promoter (0.04 kb) in four
experiments. Asterisk denotes not measured in all experiments.
(B) Nascent chromatin-bound transcripts (open bars) and H3 acety-
lation (gray bars) were quantiﬁed in IFN-g-induced cells after the
indicated times. Results represent the mean and SD from two
experiments.
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regulatory region (26). We therefore determined
whether these intergenic transcripts are also observed in
IFN-g-induced cells (Figure 6). Intergenic transcripts were
induced during the early phase of H4 acetylation, prior to
transcription of the HLA-DRA gene itself. The abundance
of these intergenic transcripts is highest just upstream of
the promoter and in regions that ﬂank the distal S0-Y0
module (Figure 6). This IFN-g-induced pattern of
intergenic transcription is similar to the one observed
previously in B cells (26).
H3 acetylation coincides with increased H3methylation
To examine where and when changes in H3 methylation
occur during IFN-g-induced expression of the HLA-DRA
gene, we performed ChIP experiments with antibodies
directed against H3K4Me3, H3K4Me2, H3R17Me2 and
H3K9Me3 (Figure 7). Increases restricted to short regions
situated near the 50 end of the HLA-DRA gene were
observed for all four modiﬁcations. The increases in
H3K4Me3, H3K4Me2 and H3K9Me3 peaked at a
position situated after the transcription initiation site.
The strongest increase in H3R17Me2 was situated at the
transcription initiation site. These methylation events
occurred mainly after 6 h, although the increase in
H3K4Me2 appeared to precede the others somewhat.
Taken together, these results show that introduction of the
H3 methylation marks overlaps temporally and spatially
with increased H3 acetylation.
All H3modifications are transcription dependent
With respect to both their timing and position, the
increases in H3 acetylation and methylation coincide
with active transcription of the HLA-DRA gene, raising
the possibility that they might actually be a consequence
of transcription. To address this possibility, we induced
cells with IFN-g for 6 h to permit the induction of CIITA
expression and completion of the early H4 acetylation
phase, and then continued the induction in the presence of
the drug 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole
(DRB) (Figure 8A), which blocks transcription elongation
by inhibiting phosphorylation of the C-terminal domain
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(CTD) of Pol II (Figure 8B) (35,36). This protocol
completely blocked the induction of HLA-DRA mRNA
accumulation (Figure 8C) and reduced Pol II density
within the body of the gene (Supplementary Figure 1).
As expected, DRB did not signiﬁcantly aﬀect HLA-DRA
promoter occupation by RFX and CIITA, the acetylation
of H4 or recruitment of Pol II to the promoter (Figure 8B
and C). Events that precede the initiation of HLA-DRA
transcription had thus been completed and were not
reversed by the addition of DRB. In contrast, the increases
in H3Ac, H3K4Me3, H3K4Me2, H3R17Me2 and
H3K9Me3, which occur mainly after 6 h, were all
completely eliminated by DRB. The introduction of
these ﬁve modiﬁcations thus behaves in a manner similar
to that of the H3K36Me3 modiﬁcation (Figure 8C), which
is known to be strictly dependent on active Pol II
elongation (2).
To ascertain that the DRB sensitivity of the H3Ac,
H3K4Me3, H3K4Me2, H3R17Me2 and H3K9Me3 mod-
iﬁcations is not a non-speciﬁc consequence of a general
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Figure 8. Most IFN-g-induced histone modiﬁcations deposited at the HLA-DRA gene are a consequence of active transcription. (A) The diagram
depicts the protocol used to document the eﬀect of DRB on IFN-g-induced HLA-DRA gene activation. (B) The eﬀect of DRB on the
phosphorylation of Pol II was assessed by western blotting (left), whereas its eﬀect on HLA-DRA promoter occupation by RFX (right) and CIITA
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Nucleic Acids Research, 2007, Vol. 35, No. 10 3437
block in the transcription of genes encoding histone-
modifying factors, we examined the levels of several key
proteins by western blotting experiments. These included
the histone acetyltransferase (HAT) factors [cyclic AMP
responsive-element binding-protein (CBP) and p300/CBP-
associated factor (pCAF)], the histone methyltransferase
(HMT) factors (Set1 and WDR5), and the H3R17-speciﬁc
HMT CARM1 (Figure 8D). We also examined the HAT
GCN5 (data not shown). No drop in the abundance of
any of these proteins was induced by the 6-h DRB
treatment.
Taken together, these results are consistent with the
model that the H3Ac, H3K4Me3, H3K4Me2, H3R17Me2
and H3K9Me3 modiﬁcations are introduced in a
transcription-coupled manner during IFN-g-induced acti-
vation of the HLA-DRA gene.
DISCUSSION
Our results demonstrate that histone modiﬁcations
associated with IFN-g-induced HLA-DRA gene activation
are introduced during two sequential phases that diﬀer
with respect to their timing, the regions of the gene that
are concerned, the precise modiﬁcations that are made and
their dependence on ongoing transcription. The ﬁrst phase
precedes the initiation of transcription and is character-
ized by a rapid increase in H4K5 and H4K8 acetylation
over a large upstream domain. The second phase is
concomitant with active transcription and is characterized
by increases in H3K9Ac, H3K4Me2, H3K4Me3,
H3K9Me3 and H3R17Me2 in short regions situated at
or within the 50 end of the gene. This second phase is
completely blocked by the transcription elongation
inhibitor DRB, indicating that it is a consequence of
active elongation by Pol II.
The timing, localization and transcription-dependence
of the increases in H3Ac, H3K4Me2, H3K4Me3,
H3K9Me3 and H3R17Me2 suggest that these marks are
introduced by HATs and HMTs that are recruited by
actively transcribing Pol II, associated elongation factors
and/or prior histone modiﬁcations that were introduced in
a transcription-dependent manner. Moreover, they imply
that most histone modiﬁcations introduced during HLA-
DRA gene activation do not play a role in facilitating
assembly of the general transcription machinery and
transcription initiation, but are instead likely to be
implicated in subsequent processes such as promoter
clearance, transcription elongation and/or the establish-
ment of transcriptional memory. These conclusions are
consistent with previous reports suggesting that phosphor-
ylation of the CTD of Pol II by the CDK7 subunit of the
general transcription factor TFIIH and the CDK9 subunit
of the transcription elongation factor pTEFb are key
events in CIITA-induced MHC-II gene expression (28,37).
In contrast, our results challenge current models propos-
ing that CIITA serves as a scaﬀolding protein that recruits
and coordinates all key chromatin-modifying activities at
MHC-II promoters, and that the modiﬁcations introduced
by these activities are primarily required for transcription
initiation at MHC-II genes (5).
Among the histone modiﬁcations we have examined,
only the rapid and long-range increase in H4 acetylation
coincides temporally with the recruitment of CIITA and
occurs prior to and independently of active transcription
of the HLA-DRA gene. This suggests that only the early
H4 acetylation phase is likely to be mediated by HATs
that are recruited directly by CIITA. HATs that are
believed to be able to cooperate with CIITA include CBP,
pCAF, GCN5 and steroid receptor co-activator (SRC)-1.
These HATs have been reported to be recruited to MHC-
II promoters in B cells and IFN-g-induced cells, can
interact with CIITA in vitro and upon over expression in
transfected cells, and can activate MHC-II reporter genes
in synergy with CIITA in transient transfection experi-
ments (38–42). However, we have so far been unable to
document a robust and reproducible recruitment of any of
these HATs in a pattern that coincides temporally and
spatially with the binding of CIITA and the early increase
in H4 acetylation. One explanation that could account for
this discrepancy is that these HATs associate only
transiently with the HLA-DRA upstream region.
Alternatively, other HATs could be implicated. Since
CIITA has been reported to have intrinsic HAT activity
(43), one possibility is that CIITA itself might be
responsible for the increase in H4 acetylation. A second
intriguing possibility is suggested by the ﬁnding that
intergenic transcription is induced in the HLA-DRA
upstream region according to a pattern that is similar to
that observed for H4 acetylation with respect to both
timing and spatial distribution. Intergenic transcription
has been attributed a regulatory function in the establish-
ment of open chromatin domains in several systems
(44–49). It has notably been suggested to contribute to the
function of locus control regions (LCRs) (44,45,49).
Among other models, it has been postulated that the
regulatory role of intergenic transcription could be due to
chromatin remodeling activities—such as HATs—that
track along the chromatin with Pol II (50–55). Since the
HLA-DRA upstream regions exhibit properties typical of
LCRs (26,56–58), it is tempting to speculate that such a
tracking mechanism is operating during the early phase of
H4 acetylation observed during HLA-DRA gene activa-
tion. We can however not exclude the possibility that the
intergenic transcription is a consequence rather than a
cause of increased H4 acetylation.
Our results highlight a dominant role of transcription
elongation in the recruitment of histone-modifying activ-
ities during the induction of MHC-II gene expression.
This is at odds with widespread models of gene regulation
postulating that HATs and HMTs are primarily recruited
by DNA-bound transcription factors and their associated
co-activators (1–3,5). However, there is growing evidence
that a decisive role of transcription elongation in the
establishment of histone modiﬁcations is not just a
peculiarity of the MHC-II system.
There is strong evidence for a link between deposition of
the H3K4Me3 mark and transcription elongation in
Saccharomyces cerevisiae. Set1—the HMT responsible
for methylating H3K4 in yeast—is recruited to the
elongating CTD-phosphorylated form of Pol II by its
interaction with the elongation factor Paf1 (2,6–8).
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This mode of recruitment is consistent with the results of
genome-wide mapping studies, which have shown that
the density of H3K4 methylation generally peaks within
the 50 transcribed portion of active yeast genes (59,60).
The link between H3K4 methylation and transcription
elongation is less well established in higher eukaryotes.
Set1 homolog in higher eukaryotes—of which there are
several—have in fact been reported to be recruited by
interactions with speciﬁc transcription factors (61–65).
However, large-scale mapping studies in Drosophila
melanogaster and humans, as well as a more limited
study in the chicken, have demonstrated that H3K4
methylation is, like in yeast, frequently concentrated
within the 50 transcribed regions of active genes (66–70).
Moreover, a protein fraction enriched in H3K4-speciﬁc
HMT activity was recently reported to introduce the
H3K4Me3 modiﬁcation in a transcription-coupled
manner in a reconstituted human in vitro transcription
system (71). These ﬁndings suggest that a transcription-
dependent mode of recruitment of H3K4-speciﬁc HMTs is
conserved in higher eukaryotes.
There are also indications that H3 acetylation may be
coupled to transcription elongation at numerous genes in
diverse species. Large-scale mapping studies performed in
S. cerevisiae, Schizosaccharomyces pombe, D. melanogaster
and humans have established that the density of H3
acetylation tends to peak, as observed here at the HLA-
DRA gene, within the 50 transcribed region of expressed
genes (59,60,67,68,70,72,73). This intragenic localization
would be consistent with a widespread role of active
transcription in increasing H3 acetylation. Transcription-
dependent H3 acetylation could be mediated by HATs,
such as the elongator complex, that travel along chroma-
tin in association with elongating Pol II (9,51–54).
Alternatively, several ﬁndings suggest that H3 acetylation
could be coupled to H3K4 methylation. Large-scale
mapping studies have shown that the patterns of H3Ac
and H3K4Me3 often coincide (59,60,67,68,70,72,73).
Moreover, methylation at K4 makes H3 a preferential
target for dynamic changes in acetylation (74). Finally,
histone-modifying complexes containing both HAT and
H3K4-speciﬁc HMT subunits have been identiﬁed in
yeast, D. melanogaster and humans (11,65,75).
The recruitment of CARM1, the HMT responsible for
making the H3R17Me2 modiﬁcation, is believed to be
mediated by interactions with speciﬁc transcription factors
or co-activators (3,14,15,32,76). However, in two systems
CARM1 recruitment has been shown to be dependent on
the prior acetylation of H3 (14,15). Tethering of CARM1
to chromatin modiﬁcations established during active
transcription, such as H3 acetylation, might thus consti-
tute an alternative pathway for CARM1 recruitment.
Finally, our results extend the recent discovery that the
H3K9Me3 mark is introduced into the 50 transcribed
region of mouse and human genes by a transcription-
elongation-dependent process (4). As observed here at the
HLA-DRA gene, this previous report also demonstrated
co-localization between the H3K9Me3 and H3K4Me3
marks, suggesting that their introduction might be
coupled (4).
Taken together, the ﬁndings outlined above suggest that
transcription elongation may play a critical role in
establishing histone-modiﬁcation patterns associated
with many actively expressed genes in species ranging
from yeast to humans. The results reported here for
activation of the HLA-DRA gene are thus likely to be of
widespread relevance to numerous gene regulatory sys-
tems in diverse species.
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